Companies Presenting Exosome Data at AACR

in Conferences, Industry News, Press Releases April 4, 2017

Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes

Improved Detection of Exosomal HAAH is Presented at the American Association for Cancer Research (AACR) Meeting in Washington, DC, April 2, 2017

GAITHERSBURG, Md., March 30, 2017 /PRNewswire/ — Panacea Pharmaceuticals, Inc. presents a paper regarding detection of the cancer biomarker HAAH at the annual American Association for Cancer Research (AACR) meeting in Washington DC held April 1-5, 2017. The paper is titled:

“Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase (HAAH)”

The paper demonstrates major refinements to Panacea’s multi-cancer HAAH-exosome detection assay that targets the cancer-specific blood serum biomarker HAAH. The cancer field is intensely focused upon exosomes, which are small cell-like nanoparticles derived from the cancer cells that are proving to be important biomarkers and mediators of cancer cell metastasis and progression.

(read more…)

Caris Life Sciences’ Results Demonstrate Ability of ADAPT Biotargeting System to Detect Breast Cancer Subtypes from Liquid Biopsy Samples

Enriched Aptamer Libraries Identified 100% of Patients with ER+/PR+/HER2- Lobular Carcinoma Breast Cancer in Pilot Study Presented at AACR 2017 Annual Meeting

IRVING, Texas, April 3, 2017 /PRNewswire/ — Caris Life Sciences^®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results of a study that demonstrate the ability of the company’s ADAPT Biotargeting System^™ to detect different molecular subtypes of breast cancer from a liquid biopsy collected from women with breast cancer. ADAPT Biotargeting System was used to develop libraries of aptamers using blood plasma exosomes to characterize system-wide changes associated with breast cancer subtypes. The study is presented today in a poster session at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C.

(read more…)